Power of ARNI in heart failure
Dr. Sidartha Lukram
MBBS, DNB, MCh,
Department of Cardio-Thoracic and Vascular Surgery,
Shija Hospital, Imphal, Manipur
Heart failure (HF) is a significant global public health issue with significant morbidity, mortality, and economic burden. Recent research has shown that angiotensin receptor-neprilysin inhibitor (ARNI), such as Sacubitril-Valsartan, can reduce cardiovascular morbidity and mortality in patients with chronic HF and reduced left ventricular ejection fraction (LVEF). This treatment has led to a decrease in cardiovascular mortality and HF hospitalizations, with a favorable safety profile. The Indian group of experts in cardiology, nephrology, and diabetes has provided a comprehensive review of the power and promise of ARNI in HF management and an evidence-based appraisal of its use as an essential treatment strategy for HF patients in clinical practice. The consensus suggests that ARNI could be beneficial for patients with 40-50% of LVEF, frequent subtle systolic dysfunction, and higher hospitalization risk.